Skip to main
ALMS
ALMS logo

Alumis Inc (ALMS) Stock Forecast & Price Target

Alumis Inc (ALMS) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alumis Inc is positioned favorably within the clinical-stage biopharmaceutical sector, focusing on innovative therapies for autoimmune disorders, underscoring its potential for significant market impact. The company has a clinical pipeline that includes promising candidates such as ESK-001, with conservative estimates projecting peak sales of $2 billion for systemic lupus erythematosus (SLE), despite a cautious 20% probability of approval suggesting substantial upside potential. The favorable comparisons to existing treatments and the strategic focus on targeted rather than broad immunosuppression indicate a significant opportunity for the company to capture a vital market share, reinforcing positive sentiment around its stock outlook.

Bears say

Alumis Inc faces several fundamental risks that contribute to a negative outlook on its stock, primarily revolving around the development and approval of its lead product, ESK-001. The inability to advance ESK-001 into pivotal trials within expected timelines, coupled with potential failures in demonstrating efficacy for psoriasis (PsO) and systemic lupus erythematosus (SLE), poses significant challenges to the company’s growth trajectory. Furthermore, delays in regulatory submissions and approvals, along with competitive pressures in the immunology and inflammation (I&I) market, may hinder market uptake while presenting risks of dilution to current investors.

Alumis Inc (ALMS) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alumis Inc (ALMS) Forecast

Analysts have given Alumis Inc (ALMS) a Buy based on their latest research and market trends.

According to 5 analysts, Alumis Inc (ALMS) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alumis Inc (ALMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.